Ireland
--:--IST
Recruiting Observational

Complications in Pediatric Mechanical Circulatory Assistance: Evaluation of Infection Management.

NCT06464016 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2023-07-04
Last updated
2025-01-28

Condition(s) studied

Heart-Assist DevicesInfectionsHeart Transplant Infection

Investigational drug(s) / intervention(s)

Ventricular Assist Device with Berlin Heart EXCOR

Ventricular Assist Device with Berlin Heart EXCOR: The Berlin Heart® EXCOR is a type of "artificial heart" pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body.

Study summary

Heart failure is a major cause of mortality and morbidity in children. Heart transplantation can significantly improve the prognosis of patients with severe heart failure, but access is limited by a shortage of transplants.

Long-term mechanical circulatory support is a major advance in the management of heart failure and can provide haemodynamic support while awaiting myocardial recovery or heart transplantation. The Berlin Heart (BH) EXCOR is the only long-term support system available for children.

Despite technical and medical advances in circulatory support, infection is a common complication and a major cause of morbidity and mortality in patients on BH.

There are few studies on the management of infection with mechanical support. Current ISHLT (International Society for Heart and Lung Transplantation) recommendations are based on expert opinion and observational studies. Some experts recommend anti-infective therapy until transplantation for specific support infections or for support-associated infections with persistent bacteraemia.

Eligibility

Sex
ALL
Min age
1 Day
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * patients under 18yo of age with Berlin Heart assisting device in Hospices Civils de Lyon, in France. Exclusion Criteria: * patients over 18 yo at the time of BH assistance * unavailable documentation

Primary outcome measure(s)

  • Relapse of VAD-infection after discontinuation of anti-infective therapy — 3 months
    Clinical and microbiological diagnosis of recurrence of infection with the same pathogen within 3 months of cessation of anti-infective therapy for a VAD-specific or VAD-related infection.

Trial sites (1)

FacilityCityRegionStatus
Hospices Civils de Lyon Lyon France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06464016 on ClinicalTrials.gov ↗ ← All trials in France